Forecasting disease progression

About us

We are an AI-driven precision medicine company developing a multimodal prognostic platform to forecast disease progression in age-related disorders. Our forecasts provide new tools to physicians for improved patient care and to pharmaceutical companies for faster drug development. Our current applications are in Alzheimer's disease.

Foresight™ - Our Predictive Platform


Our platform can leverage multiple sources of data (imaging, genetic, phenotypic, molecular and clinical variables) to better characterize individuals.

High precision targeting

We are able to rapidly and precisely target subgroups of interest in large, heterogeneous populations.

Highly actionable insights

Our digital biomarkers are highly specific and thoroughly validated, making them ready for action in any clinical setting.

To learn more, visit our Publications page!

Latest News

Perceiv AI to present its latest results on mitigating loss of statistical power due to outcome imbalance in clinical trials

November 24, 2022 | Montreal, Canada | Announcement

Join Perceiv AI's senior scientist Angela Tam at our poster #LP005 "Mitigating loss of statistical power due to outcome imbalance in clinical trials" on Tuesday November 29 to Wednesday November 30 at Clinical Trials on Alzheimer's Disease (CTAD) 2022. Our team is excited to meet you in San Francisco, California next week.

Oral presentation at Alzheimer's Association International Conference (AAIC 2022)

July 18, 2022 | Montreal, Canada

Join Senior Scientist Dr. Angela Tam as she will give a talk on Perceiv AI’s latest work and performance gain for trial optimization and patients selection at the 2022 Alzheimer's Association International Conference (AAIC 2022) in the Novel Clinical Trial Designs and Outcome Measures session. Dr. Tam’s oral presentation will take place on August 2nd at 9:55am PT at the San Diego Convention Center. More info at:

Find all our past news and announcements in our Newsroom!

Meet our Team

Christian Dansereau, Ph.D.

CEO & Founder


César Laurent, Ph.D.

CTO & Founder


Angela Tam, Ph.D.

Senior Scientist


Adrián Noriega de la Colina, M.D., Ph.D.

Clinical and Regulatory Lead


Meet our Advisors

Yoshua Bengio

Yoshua Bengio, Ph.D.

Full Professor at Université de Montréal,

Founder and Scientific Director of Mila,

Scientific Director of IVADO

Serge Gauthier

Serge Gauthier, M.D.

Full Professor at McGill University,

Director of the Alzheimer Disease and Related Disorders Research Unit, Douglas Research Centre

Betsabeh Madani Hermann

Betsabeh Madani Hermann, M.B.A.

Healthcare executive & investor,

VP strategy and BD at Philips


Partners & Collaborators

Mila - Quebec AI Institute
vTv Therapeutics Inc.
Acasti Pharma Inc.
DalCor Pharmaceuticals
Montreal Heart Institute - Institut de Cardiologie de Montréal
CCNA - Canadian Consortium on Neurodegeneration in Aging
CHUM - Centre hospitalier de l'Université de Montréal
Douglas Mental Health University Institute
McGill University

Supported by

CQDM - Consortium de recherche biopharmaceutique
CLSI - California Life Sciences Institute
CTA - Canadian Technology Accelerators
Montréal Invivo
District 3 Innovation Hub
CTS - Campus des Technologies de la Santé